BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Dexpramipexole

The (R)-(+) enantiomer of PRAMIPEXOLE. Dexpramipexole has lower affinity for DOPAMINE RECEPTORS than pramipexole.

50+ PubMed studies analyzed · 9 RCTs · Evidence Score: 50.8

Research Domains

Dexpramipexole has been studied across 21 research domains including 🧠 Neuroprotection, ⚡ Energy & Fatigue, 🔬 Inflammation, 🧠 Focus & Attention, 🌤️ Mood & Depression. The primary research focus is 🧠 Neuroprotection with 24% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Dexpramipexole, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

bdb
2 shared targets
Dihydroergocornine
2 shared targets
dicyclomine
2 shared targets
bdb
2 shared targets
desloratadine
2 shared targets
quinacrine
2 shared targets
ketotifen
2 shared targets
loperamide
2 shared targets
bdb
2 shared targets
doxepin
2 shared targets
Loading evidence profile...

This evidence profile for Dexpramipexole is generated deterministically from 50 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.